810ORANDOMIZED, DOSE-RANGING PHASE II TRIAL OF NIVOLUMAB FOR METASTATIC RENAL CELL CARCINOMA (MRCC).

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Motzer, RJ; Rini, BI; McDermott, DF; Redman, B; Kuzel, T; Harrison, MR; Vaishampayan, UN; Drabkin, H; George, S; Logan, T; Margolin, K; Plimack, ER; Waxman, I; Lambert, A; Hammers, H

Published Date

  • September 1, 2014

Published In

Volume / Issue

  • 25 / suppl_4

Start / End Page

  • iv281 -

PubMed ID

  • 28172310

Pubmed Central ID

  • 28172310

Electronic International Standard Serial Number (EISSN)

  • 1569-8041

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdu337.3

Conference Location

  • England